// App-Quantinova.ai

1435 : NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

Researchers

Presenter

  • Eliana Ruggiero

Principal Investigators

  • Dai Liu

  • Aaron Prodeus

  • Amy M Becker

  • Maxwell Foisey

  • Ishina Balwani

  • Ivy Dutta

  • Qingzhan Zhang

  • Simo M Arredouani

  • Mark McKee

  • Fabio Ciceri

  • Laura Sepp-Lorenzino

  • Chiara Bonini

  • Birgit C Schultes

Medical Centers

  • Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Disease, IRCCS San Raffaele Scientific Institute,

  • Cell Therapy, Intellia Therapeutics, Cambridge, MA

  • Clinical Development, Intellia Therapeutics, Cambridge, MA

  • San Raffaele Scientific Unit, Hematology and Bone Marrow Transplantation Unit, Milano, Italy

  • Pathology Unit, San Raffaele H. Scientific Institute, Milano, Italy

  • Intellia Therapeutics, Cambridge, MA

  • Vita-Salute San Raffaele University, Milan, Italy

Locations

  • Italy

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Solid malignancies

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Major Histocompatibility Complex, Class I, A

  • T cell receptor alpha locus

Drug/Treatment

  • IL-15

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved